Litt's app available free to subscribers - download for IOS and Android from the App Store or Google Play.
- TRADE NAME: Gattex (Hospira)
- INDICATIONS: Treatment of short bowel syndrome in adult patients dependent on parenteral support
- CLASS: Glucagon-like peptide-2 (GLP-2) analog
- HALF-LIFE: 1–2 hours
- FDA APPROVAL DATE: 12/21/2012
- CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:
None known
Please login to view the rest of this drug profile.
Click on the DRUG REVIEW ARTICLE links (above) to see two reviews of teduglutide in the Taylor & Francis journal Expert Opinion on Drug Safety.
(Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 04/13/2025
